|
Sunday, 08/01/2010
|
Adaptive Designs in Dose-Finding Oncology Drug Combination Trials
Yuehui Wu, GlaxoSmithKline; Bingming Yi, GlaxoSmithKline; Yanmei Xu, GlaxoSmithKline
2:45 PM
|
Evaluation of Dose-Finding Designs: On the Interplay Between Theory and Simulation
Assaf P. Oron, University of Washington; Peter Hoff, University of Washington
3:05 PM
|
Expect the Unexpected: Bayesian Adaptive Dose-Finding Design in Proof-of-Concept Study
Feng Liu, GlaxoSmithKline
3:25 PM
|
A Bayesian Dose-Finding Design Adapting to Efficacy and Tolerability Response
S. Krishna Padmanabhan, Pfizer Inc.; Scott Berry, Berry Consultants, LLC; Vladimir Dragalin, Pfizer Inc.; Michael Krams, Pfizer Inc.
5:05 PM
|
|
Wednesday, 08/04/2010
|
Phase I Dose-Finding in Cancer Trials Based on a Discrete Time Multistate Model
Lin Yang, MD Anderson Cancer Center; Nebiyou Bekele, MD Anderson Cancer Center; Donald Arthur Berry, MD Anderson Cancer Center
8:50 AM
|
Key Considerations for Simulations to Optimize Dose-Finding Trials
Natalie Cheung Hall, Eli Lilly and Company
10:35 AM
|
Stopping Rules for Bayesian Dose-Finding Oncology Trials
Yanqiong Zhang, Sanofi-Aventis; Yi He, sanofi-aventis; Guillaume Marchand, sanofi-aventis; Pierre Mancini, sanofi-aventis; Sandrine Micallef, sanofi-aventis
10:50 AM
|
A Dose-Finding Method in Joint Modeling of Efficacy and Safety: An Extension of the MCP-Mod Method
Aiyang Tao, Novartis; Yong Lin, University of Medicine and Dentistry of New Jersey; Jose Carlos Pinheiro, Johnson & Johnson; Weichung J. Shih, University of Medicine and Dentistry of New Jersey
11:35 AM
|
|